 | |
| Names | |
|---|---|
| Preferred IUPAC name N-[2-(3,4-Dimethoxyphenyl)ethyl]-N-methyl-3-{4-[2-(propan-2-yl)indolizine-1-sulfonyl]phenoxy}propan-1-amine | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| UNII | |
| |
| |
| Properties | |
| C31H38N2O5S | |
| Molar mass | 550.71 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Fantofarone is acalcium channel blocker.[1]
There are many different calcium channel blockers that show different results in use. Fantofarone andverapamil are both calcium channel blockers that behave differently in different applications.
Fantofarone was shown in use for treatment of angioplasty-inducedvasospasm in an atherosclerotic rabbits.[2] There are many different observations that show a potential cause of vasospasm, such as local injury on the body, but overall mechanism of it is still not fully understood.[2] In order to observe the efficiency of fantofarone in the treatment ofangioplasty-inducedvasospasm (AIV), it was compared to the treatment of verapamil (which is also a calcium channel blocker). Fantofarone showed more effectiveness against a severity of vasospasm than verapamil.[2]
Fantofarone and verapamil were also tested as an attempt of reversing resistance tochloroquine,[3] a medication that is used to treat malaria. In the treatment of reversing the chloroquine resistance it was observed that verapamil was more potent and more efficient than fantofarone.[3]
